Market revenue in 2023 | USD 1,035.3 million |
Market revenue in 2030 | USD 2,400.6 million |
Growth rate | 12.8% (CAGR from 2023 to 2030) |
Largest segment | Bioreactors/fermenters |
Fastest growing segment | Cell Culture Products |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Bioreactors/Fermenters, Cell Culture Products, Filters, Bioreactors Accessories, Bags & Containers |
Key market players worldwide | Thermo Fisher Scientific Inc, Merck KGaA, Corning Inc, Sartorius AG, Eppendorf, Danaher Corp, Boehringer Ingelheim, Getinge AB Class B, Lonza Group Ltd, Avantor Inc, Repligen Corp, Entegris Inc, PBS Biotech, Meissner, Kuhner Shaker |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to upstream bioprocessing market will help companies and investors design strategic landscapes.
Bioreactors/fermenters was the largest segment with a revenue share of 31.28% in 2023. Horizon Databook has segmented the UK upstream bioprocessing market based on bioreactors/fermenters, cell culture products, filters, bioreactors accessories, bags & containers covering the revenue growth of each sub-segment from 2018 to 2030.
The upstream bioprocessing market in the UK is driven by the presence of numerous bioprocessing companies, such as Thermo Fisher Scientific Inc., ESI Ultrapure, and IDBS, among others. These companies undertake various business initiatives to gain maximum market share, contributing to the upstream bioprocessing market growth in the country.
For instance, in November 2023, Lonza, a well known biotechnology company, announced the purchase of a plot in the UK. This purchase is expected to offer an additional development potential and would enable Lonza to expand in the UK’s upstream bioprocessing market.
Furthermore, in September 2023, FUJIFILM Diosynth Biotechnologies, a Contract Development And Manufacturing Organization (CDMO) partner for manufacturing & developing vaccines, biologics, oncolytic viruses, and gene & cell therapies, launched a new facility in the UK. This facility is now operational for manufacturing of oncolytic viruses, viral gene therapies, and vaccines for clinical trials.
Horizon Databook provides a detailed overview of country-level data and insights on the UK upstream bioprocessing market , including forecasts for subscribers. This country databook contains high-level insights into UK upstream bioprocessing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account